Shares of Aptevo Therapeutics Inc (NASDAQ:APVO) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price objective of $6.00 for the company and are predicting that the company will post ($0.32) earnings per share for the current quarter, according to Zacks. Zacks has also given Aptevo Therapeutics an industry rank of 179 out of 265 based on the ratings given to related companies.
A number of equities analysts have issued reports on the stock. ValuEngine lowered shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 10th. Piper Jaffray Companies reissued an “overweight” rating and set a $6.00 price target on shares of Aptevo Therapeutics in a research report on Thursday, October 5th.
Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.25 by ($2.11). Aptevo Therapeutics had a negative return on equity of 28.03% and a net margin of 5.40%. equities research analysts forecast that Aptevo Therapeutics will post 0.43 EPS for the current fiscal year.
In other Aptevo Therapeutics news, VP Randy Joe Maddux purchased 25,000 shares of Aptevo Therapeutics stock in a transaction on Wednesday, November 15th. The stock was bought at an average cost of $2.76 per share, with a total value of $69,000.00. Following the transaction, the vice president now owns 25,000 shares of the company’s stock, valued at approximately $69,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 15.60% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC raised its position in Aptevo Therapeutics by 87.2% during the 4th quarter. Acadian Asset Management LLC now owns 67,799 shares of the biotechnology company’s stock worth $287,000 after buying an additional 31,578 shares during the last quarter. Legal & General Group Plc raised its position in Aptevo Therapeutics by 11,751.3% during the 2nd quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock worth $815,000 after buying an additional 390,379 shares during the last quarter. Precept Management LLC purchased a new position in Aptevo Therapeutics during the 2nd quarter worth approximately $1,210,000. Finally, Dimensional Fund Advisors LP raised its position in Aptevo Therapeutics by 8.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock worth $2,187,000 after buying an additional 78,109 shares during the last quarter. 32.13% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Aptevo Therapeutics Inc (APVO) Receives Average Recommendation of “Strong Buy” from Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/20/aptevo-therapeutics-inc-apvo-receives-average-recommendation-of-strong-buy-from-analysts.html.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.